Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Critical Limb Ischemia - Pipeline Review, H2 2019, provides an overview of the Critical Limb Ischemia (Cardiovascular) pipeline landscape.
Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet or toes, sores, skin infections will not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality of life and increasing survival.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Critical Limb Ischemia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Critical Limb Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Critical Limb Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 3, 15, 3, 1 and 10 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Critical Limb Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Critical Limb Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Critical Limb Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Critical Limb Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Critical Limb Ischemia (Cardiovascular)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Critical Limb Ischemia (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Critical Limb Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Critical Limb Ischemia - Overview
Critical Limb Ischemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Critical Limb Ischemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Critical Limb Ischemia - Companies Involved in Therapeutics Development
Anaeropharma Science Inc
Antidote Therapeutics Inc
apceth Biopharma GmbH
Athersys Inc
BiogenCell Ltd
Biotech Holdings
Caladrius Biosciences Inc
Constant Therapeutics LLC
Cynata Therapeutics Ltd
Helixmith Co Ltd
Hemostemix Inc
Histocell SL
ID Pharma Co Ltd
Integene International Holdings LLC
Juventas Therapeutics Inc
Kang Stem Biotech Co Ltd
Libella Gene Therapeutics
LifeCells LLC
Nissan Chemical Corp
Pharmicell Co Ltd
Pluristem Therapeutics Inc
ReNeuron Group Plc
Reven Pharmaceuticals Inc
Rexgenero Ltd
TaiGen Biotechnology Co Ltd
Taiwan Bio Therapeutics Co Ltd
Theratome Bio Inc
U.S. Stem Cell Inc
VESSL Therapeutics Ltd
Yichang Humanwell Pharmaceutical Co Ltd
Critical Limb Ischemia - Drug Profiles
ACP-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AdipoCell - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Alecmestencel-T - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASCT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATI-1013 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGC-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biochymal - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
burixafor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Cardiovascular Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellgram-CLI - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLBS-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CYP-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
donaperminogene seltoplasmid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DVC-10101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emiplacel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Critical Limb Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate FGF2 for Critical Limb Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate HGF for Critical Limb Ischemia and Chronic Post-Operative Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate TERT for Alzheimer's Disease, Ageing and Critical Limb Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HC-016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JVS-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Multistem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pitavastatin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Procell - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rejuveinix - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ReN-009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REX-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REX-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REX-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Critical Limb Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Thera-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TXA-302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Critical Limb Ischemia - Dormant Projects
Critical Limb Ischemia - Discontinued Products
Critical Limb Ischemia - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Critical Limb Ischemia, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Universities/Institutes, H2 2019
Table 5: Products under Development by Companies, H2 2019
Table 6: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 7: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 8: Products under Development by Universities/Institutes, H2 2019
Table 9: Number of Products by Stage and Target, H2 2019
Table 10: Number of Products by Stage and Mechanism of Action, H2 2019
Table 11: Number of Products by Stage and Route of Administration, H2 2019
Table 12: Number of Products by Stage and Molecule Type, H2 2019
Table 13: Critical Limb Ischemia - Pipeline by Anaeropharma Science Inc, H2 2019
Table 14: Critical Limb Ischemia - Pipeline by Antidote Therapeutics Inc, H2 2019
Table 15: Critical Limb Ischemia - Pipeline by apceth Biopharma GmbH, H2 2019
Table 16: Critical Limb Ischemia - Pipeline by Athersys Inc, H2 2019
Table 17: Critical Limb Ischemia - Pipeline by BiogenCell Ltd, H2 2019
Table 18: Critical Limb Ischemia - Pipeline by Biotech Holdings, H2 2019
Table 19: Critical Limb Ischemia - Pipeline by Caladrius Biosciences Inc, H2 2019
Table 20: Critical Limb Ischemia - Pipeline by Constant Therapeutics LLC, H2 2019
Table 21: Critical Limb Ischemia - Pipeline by Cynata Therapeutics Ltd, H2 2019
Table 22: Critical Limb Ischemia - Pipeline by Helixmith Co Ltd, H2 2019
Table 23: Critical Limb Ischemia - Pipeline by Hemostemix Inc, H2 2019
Table 24: Critical Limb Ischemia - Pipeline by Histocell SL, H2 2019
Table 25: Critical Limb Ischemia - Pipeline by ID Pharma Co Ltd, H2 2019
Table 26: Critical Limb Ischemia - Pipeline by Integene International Holdings LLC, H2 2019
Table 27: Critical Limb Ischemia - Pipeline by Juventas Therapeutics Inc, H2 2019
Table 28: Critical Limb Ischemia - Pipeline by Kang Stem Biotech Co Ltd, H2 2019
Table 29: Critical Limb Ischemia - Pipeline by Libella Gene Therapeutics, H2 2019
Table 30: Critical Limb Ischemia - Pipeline by LifeCells LLC, H2 2019
Table 31: Critical Limb Ischemia - Pipeline by Nissan Chemical Corp, H2 2019
Table 32: Critical Limb Ischemia - Pipeline by Pharmicell Co Ltd, H2 2019
Table 33: Critical Limb Ischemia - Pipeline by Pluristem Therapeutics Inc, H2 2019
Table 34: Critical Limb Ischemia - Pipeline by ReNeuron Group Plc, H2 2019
Table 35: Critical Limb Ischemia - Pipeline by Reven Pharmaceuticals Inc, H2 2019
Table 36: Critical Limb Ischemia - Pipeline by Rexgenero Ltd, H2 2019
Table 37: Critical Limb Ischemia - Pipeline by TaiGen Biotechnology Co Ltd, H2 2019
Table 38: Critical Limb Ischemia - Pipeline by Taiwan Bio Therapeutics Co Ltd, H2 2019
Table 39: Critical Limb Ischemia - Pipeline by Theratome Bio Inc, H2 2019
Table 40: Critical Limb Ischemia - Pipeline by U.S. Stem Cell Inc, H2 2019
Table 41: Critical Limb Ischemia - Pipeline by VESSL Therapeutics Ltd, H2 2019
Table 42: Critical Limb Ischemia - Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, H2 2019
Table 43: Critical Limb Ischemia - Dormant Projects, H2 2019
Table 44: Critical Limb Ischemia - Dormant Projects, H2 2019 (Contd..1), H2 2019
Table 45: Critical Limb Ischemia - Discontinued Products, H2 2019
List of Figures
Figure 1: Number of Products under Development for Critical Limb Ischemia, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products by Targets, H2 2019
Figure 4: Number of Products by Stage and Targets, H2 2019
Figure 5: Number of Products by Mechanism of Actions, H2 2019
Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Top 10 Routes of Administration, H2 2019
Figure 8: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 9: Number of Products by Molecule Types, H2 2019
Figure 10: Number of Products by Stage and Molecule Types, H2 2019
